Journal of Digestive Cancer Reports

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지

Role of Liquid Biopsies in Colorectal Cancer

대장암에서 액체 생검의 역할

  • Kim, Sang Hyun (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine) ;
  • Keum, Bora (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine)
  • 김상현 (고려대학교 의과대학 내과학교실, 고려대학교 안암병원 소화기내과) ;
  • 금보라 (고려대학교 의과대학 내과학교실, 고려대학교 안암병원 소화기내과)
  • Received : 2020.06.01
  • Accepted : 2020.06.10
  • Published : 2020.06.30

⟨ Previous Next ⟩

Abstract

In recent years, liquid biopsy has received immense attention. Liquid biopsy is a minimally invasive method used for obtaining biological fluids including urine, pleural fluid and, mostly, peripheral blood. Liquid biopsy involves various targets including circulating tumors cells (CTCs), circulating cell-free tumor DNA (ctDNA), and microRNA (miRNA). Colorectal cancer (CRC), like other solid tumors, shed tumor cells into the bloodstream. Analysis of these CTCs, as well as ctDNA is the primary objective of the liquid biopsy. Evaluation of CTC or ctDNA offers information about early tumor release, development of tumor metastasis and also about mechanisms involved in tumor resistance to treatment.

Keywords

References

  1. Siegel RL, Miller KD, Goding SA, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin 2020;22:1-3.
  2. Normanno N, Cervantes A, Ciardiello F, De Luca A, Pinto C. The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. Cancer Treat Rev 2018;70:1-8. https://doi.org/10.1016/j.ctrv.2018.07.007
  3. Herrera M, Galindo-Pumarino C, Garcia-Barberan V, Pena C. A snapshot of the tumor microenvironment in colorectal cancer: the liquid biopsy. Int J Mol Sci 2019;20.
  4. Burz C, Rosca A, Pop VV, et al. Liquid biopsy challenge and hope in colorectal cancer. Expert Rev Mol Diagn 2019;19:341-348. https://doi.org/10.1080/14737159.2019.1597708
  5. Nordgard O, Tjensvoll K, Gilje B, Soreide K. Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer. Br J Surg 2018;105:e110-e120. https://doi.org/10.1002/bjs.10782
  6. Saini A, Pershad Y, Albadawi H, et al. Liquid biopsy in gastrointestinal cancers. Diagnostics (Basel) 2018;8.
  7. Lopez A, Harada K, Mizrak KD, Dong X, Song S, Ajani JA. Liquid biopsies in gastrointestinal malignancies: when is the big day? Expert Rev Anticancer Ther 2018;18:19-38.
  8. Yamada T, Matsuda A, Koizumi M, et al. Liquid biopsy for the management of patients with colorectal cancer. Digestion 2019;99:39-45. https://doi.org/10.1159/000494411
  9. Iinuma H, Watanabe T, Mimori K, et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol 2011;29:1547-1555. https://doi.org/10.1200/JCO.2010.30.5151
  10. Zhao R, Cai Z, Li S, et al. Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer. Oncotarget 2017;8:9293-9302. https://doi.org/10.18632/oncotarget.14065
  11. Sutton TL, Walker BS, Wong MH. Circulating hybrid cells join the fray of circulating cellular biomarkers. Cell Mol Gastroenterol Hepatol 2019;8:595-607. https://doi.org/10.1016/j.jcmgh.2019.07.002
  12. Gabriel E, Bagaria SP. Assessing the impact of circulating tumor DNA (ctDNA) in patients with colorectal cancer: separating fact from fiction. Front Oncol 2018;8:297. https://doi.org/10.3389/fonc.2018.00297
  13. Umetani N, Kim J, Hiramatsu S, et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem 2006;52:1062-1069. https://doi.org/10.1373/clinchem.2006.068577
  14. Wills B, Gorse E, Lee V. Role of liquid biopsies in colorectal cancer. Curr Probl Cancer 2018;42:593-600. https://doi.org/10.1016/j.currproblcancer.2018.08.004
  15. Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016;8:346.
  16. Furuki H, Yamada T, Takahashi G, et al. Evaluation of liquid biopsies for detection of emerging mutated genes in metastatic colorectal cancer. Eur J Surg Oncol 2018;44:975-982. https://doi.org/10.1016/j.ejso.2018.01.224